Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvonne Huber

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Deutsches Arzteblatt International|February 9, 2021
Tumor Incidence in Patients with Non-Alcoholic Fatty Liver DiseaseYvonne Huber, Christian Labenz, Maurice Michel, et al.
Scientific Reports|March 10, 2019
Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLDNadine Gehrke, Jana Biedenbach, Yvonne Huber, et al.
JMIR Research Protocols|May 24, 2018
Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical TrialsDaniel Pfirrmann, Nils Haller, Yvonne Huber, et al.
European Journal of Internal Medicine|September 19, 2019
Health-related quality of life in patients with compensated and decompensated liver cirrhosisChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
Hepatology Communications|November 9, 2019
Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein CholesterolChristian Labenz, Jürgen H Prochaska, Yvonne Huber, et al.
AIDS (London, England)|July 18, 2022
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIVMaurice Michel, Christian Labenz, Alisha Wahl, et al.
Oncotarget|September 17, 2017
Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activationNadine Gehrke, Marcus A Wörns, Amrit Mann, et al.
Clinical and Translational Gastroenterology|June 23, 2020
Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing StrategiesChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
The American Journal of Gastroenterology|March 9, 2019
Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With CirrhosisChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
Alimentary Pharmacology & Therapeutics|October 5, 2019
Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathyChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Deutsches Arzteblatt International|February 9, 2021
Tumor Incidence in Patients with Non-Alcoholic Fatty Liver DiseaseYvonne Huber, Christian Labenz, Maurice Michel, et al.
Scientific Reports|March 10, 2019
Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLDNadine Gehrke, Jana Biedenbach, Yvonne Huber, et al.
JMIR Research Protocols|May 24, 2018
Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical TrialsDaniel Pfirrmann, Nils Haller, Yvonne Huber, et al.
European Journal of Internal Medicine|September 19, 2019
Health-related quality of life in patients with compensated and decompensated liver cirrhosisChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
Hepatology Communications|November 9, 2019
Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein CholesterolChristian Labenz, Jürgen H Prochaska, Yvonne Huber, et al.
AIDS (London, England)|July 18, 2022
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIVMaurice Michel, Christian Labenz, Alisha Wahl, et al.
Oncotarget|September 17, 2017
Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activationNadine Gehrke, Marcus A Wörns, Amrit Mann, et al.
Clinical and Translational Gastroenterology|June 23, 2020
Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing StrategiesChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
The American Journal of Gastroenterology|March 9, 2019
Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With CirrhosisChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
Alimentary Pharmacology & Therapeutics|October 5, 2019
Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathyChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
Pageof 5